Meeting
2013 ASCO Annual Meeting
Italian cohort of ipilimumab expanded access programme (EAP): Efficacy, safety, and correlation with mutation status in metastatic melanoma patients.
Authors
Paola Queirolo
Department of Medical Oncology A, National Institute for Cancer Research, Genoa, Italy
Paola Queirolo , Francesco Spagnolo , Maresa Altomonte , Vanna Chiarion-Sileni , Jacopo Pigozzo , Michele Del Vecchio , Lorenza Di Guardo , Ruggero Ridolfi , Alessandro Scoppola , Pier Francesco Ferrucci , Virginia Ferraresi , Maria Grazia Bernengo , Michele Guida , Riccardo Marconcini , Mario Mandalà , Giorgio Parmiani , Gaetana Rinaldi , Massimo Aglietta , Ester Simeone , Paolo Antonio Ascierto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 31, 2013 (suppl; abstr 9070)
DOI
10.1200/jco.2013.31.15_suppl.9070
Abstract #
9070
Poster Bd #
48A
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: Data from the Italian cohort of ipilimumab expanded access programme (EAP).
First Author: Paolo Antonio Ascierto
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner
Poster
2015 ASCO Annual Meeting
Efficacy of high-dose adjuvant interferon therapy in high-risk melanoma harboring gene mutations.
First Author: Xuan Wang
Poster
2014 ASCO Annual Meeting
Droplet digital PCR monitoring of BRAF and NRAS plasma DNA as biomarkers of treatment response in stage IV melanoma.
First Author: David Polsky